Examples of using Simponi in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
How Simponi is given?
At the start, your doctor or nurse may inject Simponi.
If active tuberculosis is diagnosed, Simponi therapy must not be initiated see section 4.3.
You should not receive certain(live) vaccines while using Simponi.
Simponi is available as pre-filled pens and syringes(50 and 100 mg) containing a solution for injection under the skin.
People also translate
Among patients remaining in the study and treated with Simponi, DAS28 responses were similar from week 104 through week 256.
Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Patients were randomised to receive placebo+ MTX, Simponi 50 mg+ MTX, Simponi 100 mg+ MTX or Simponi 100 mg+ placebo.
Based on the subset of patients with≥ 3% BSA involvement at baseline, 79 patients(69.9%)in the placebo group and 109(74.3%) in the Simponi 50 mg group.
Before starting treatment with Simponi, all patients must be evaluated for both active and inactive(‘latent') tuberculosis.
Statistically significant improvements in signs and symptoms of severe active nr-AxialSpA were demonstrated in patients treated with Simponi 50 mg compared to placebo at week 16 Table 6.
Among patients who received Simponi maintenance treatment, the improvement in quality of life as measured by IBDQ was maintained through week 54.
Bacterial(including sepsis and pneumonia), mycobacterial(including TB), invasive fungal and opportunistic infections, including fatalities,have been reported in patients receiving Simponi.
Of the patients who received Simponi, 59%(82 out of 138) had 20% reductions after 14 weeks, compared with 22% of patients who were given placebo 17 out of 78.
In the first study, in which patients were also given methotrexate, after 14 weeks,55% patients who received Simponi(49 out of 89) achieved 20% reductions compared with 33%(44 out of 133) of patients who received placebo.
The company that markets Simponi must provide educational packs for doctors who prescribe Simponi with information on the safety of the medicine.
In the first study,around 51% of patients receiving induction treatment with Simponi(starting at 200 mg) responded to treatment after 6 weeks, compared with around 30% of patients given placebo.
Simponi is not recommended for children weighing less than 40 kg with polyarticular juvenile idiopathic arthritis or in children and adolescents younger than 18 years for any other condition.
Among patients remaining in the study and treated with Simponi, improvements in physical function and health-related quality of life were similar from week 24 through week 256.
Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with MTX.
In the second study, after 14 weeks, 35% of patients who received Simponi alone(54 out of 153) achieved 20% reductions compared with 18% of patients who received placebo 28 out of 155.
Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease(see section 5.1) and to improve physical function.
In the second study, around 50% of patients receiving maintenance treatment with Simponi 100 mg and around 47% of those given Simponi 50 mg responded to treatment after 54 weeks, compared with around 31% of patients given placebo.
Simponi 50 mg treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment at week 24 as measured by change from baseline in total modified vdH-S Score mean± SD score was 0.27± 1.3 in the placebo group compared with -0.16± 1.3 in the Simponi group; p 0.011.
Treatment with TNF blockers such as Simponi may result in reactivation of HBV in patients who carry this virus, which can be life-threatening in some cases.
Simponi is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein(CRP) and/or magnetic resonance imaging(MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs NSAIDs.
Among patients who remained on the Simponi treatment to which they were randomised at study start, DAS28 and HAQ DI responses were maintained through week 104.
For rheumatoid arthritis, Simponi was compared with placebo(a dummy treatment) in three studies involving 1,542 patients with moderate to severe rheumatoid arthritis, including patients who had not received or responded adequately to other treatments.
Patients receiving Simponi should be monitored closely for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis, patients who are on treatment for latent tuberculosis, or patients who were previously treated for tuberculosis infection.
The efficacy of Simponi was demonstrated in three multi-centre, randomised, double-blind, placebo-controlled studies in over 1500 patients≥ 18 years of age with moderately to severely active RA diagnosed according to American College of Rheumatology(ACR) criteria for at least 3 months prior to screening.